Narrative review

Deep vein thrombosis: update on diagnosis and

management
Paul C Kruger 1,2,3, John W Eikelboom3,4, James D Douketis 4,5, Graeme J Hankey6

V
enous thromboembolism (VTE) most commonly man- Summary
ifests as lower extremity deep vein thrombosis (DVT)
and pulmonary embolism and has an annual incidence • Diagnosis of deep vein thrombosis (DVT) requires a multifaceted
approach that includes clinical assessment, evaluation of pre-test
of 1–2 per 1000 population.1 Mortality is high; death within probability, and objective diagnostic testing.
30 days occurs in about 6% of patients with DVT, primarily
through pulmonary embolism, and in 13% of patients with
• Common symptoms and signs of DVT are pain, swelling, ery-
thema and dilated veins in the affected limb.
pulmonary embolism.2 Among treated patients, about 20–50% • The pre-test probability of DVT can be assessed using a clinical
develop post-­t hrombotic syndrome (PTS) after DVT, and 3% de- decision rule that stratifies DVT into “unlikely” or “likely”. If DVT
velop chronic thromboembolic pulmonary hypertension after is “unlikely”, refer for D-dimer test. If the D-dimer level is normal,
pulmonary embolism.3,4 After 3–6 months of anticoagulation, DVT can be excluded; if the D-dimer level is increased, refer for
VTE recurs in up to 40% of patients within 10 years. The risk of compression ultrasound. If DVT is “likely”, refer for compression
recurrence is two-­to threefold higher after unprovoked than ultrasound.
provoked VTE.5,6 • When DVT is confirmed, anticoagulation is indicated to control
symptoms, prevent progression and reduce the risk of post-
In the past decade, there have been notable advances in risk pre- thrombotic syndrome and pulmonary embolism.
diction, diagnosis and treatment with direct oral anticoagulants • Anticoagulation may consist of a parenteral anticoagulant over-
(DOACs), thrombolysis and catheters. Nevertheless, there re- lapped by warfarin or followed by a direct oral anticoagulant
(DOAC) (dabigatran or edoxaban), or of a DOAC (apixaban or ri-
mains uncertainty about the optimal duration of anticoagulation
varoxaban) without initial parenteral therapy.
after unprovoked VTE, indications for thrombophilia screening,
and the role of catheter-­directed thrombolysis.7 • DOACs are the preferred treatment for DVT because they are
at least as effective, safer and more convenient than warfarin.
This review summarises contemporary evidence on the diag- DOACs may require dose reduction or avoidance in patients with
nosis and management of DVT. We searched PubMed for rele- renal dysfunction, and should be avoided in pregnancy.
vant articles, from 1996 to 2019, using the search terms “venous • Recent evidence shows that DVT in patients with cancer may be
treated with edoxaban (after discontinuation of 5 days of initial
thromboembolism”, “deep vein thrombosis”, “pulmonary em- heparin or low molecular weight heparin [LMWH]) or rivaroxaban
bolism”, “thrombosis”, “anticoagulant” and “anticoagulation”. if patients prefer not to have daily injections of LMWH, but the
An accompanying article addresses pulmonary embolism.8 risk of gastrointestinal bleeding is higher with DOACs than with
Guidelines from the Thrombosis and Haemostasis Society of LMWH in patients with gastrointestinal cancer.
Australia and New Zealand (THANZ) underpin evidenced-­
based recommendations,9 which have been graded according
to the National Health and Medical Research Council levels of
evidence (Box 1).10
Pre-­test probability using a clinical decision rule
In primary care and in outpatients with suspected DVT, the
Diagnosis
Wells rule for DVT helps calculate the pre-­test probability of
DVT and guide investigations.9 The Wells rule assigns points for
The clinical presentation of DVT is often non-­specific. Hence,
clinical symptoms and risk factors for DVT to produce a total
accurate diagnosis requires sequential integration of clinical
score between −2 and 9 points, which stratifies patients as “un-
features, assessment of pre-­test clinical probability, and confirm-
likely” (≤ 1 point) or “likely” (≥ 2 points) to have DVT.15 A poten-
atory investigations that include D-­dimer testing and imaging.
tial weakness is the need for clinicians to subjectively determine
Symptoms and signs of deep vein thrombosis whether an alternative (non-­DVT) diagnosis is likely or unlikely,
as both groups require investigations.
Symptoms and signs of leg or pelvis DVT include leg pain,
swelling, erythema and dilated superficial veins. Arm DVT has Among inpatients with suspected DVT, imaging is required
similar symptoms localised to the arm. Some DVTs are asymp- because clinical decision rules have not been validated and
tomatic. Differential diagnoses for limb DVT include cellulitis, ­D-­dimer testing has a high frequency of false positive results.
lymphoedema, chronic venous insufficiency, haematoma and,
for leg DVT, ruptured Baker cyst.11 D-­dimer testing
MJA 210 (11) ▪ 17 June 2019

D-­dimer levels are raised in most patients with DVT (sensi-

Pre-­test clinical gestalt or impression tivity, 94–96%) and also in older patients and in patients with
The gestalt probability of DVT is an unstructured impression of malignancy, sepsis, inflammation, chronic kidney failure, re-
the likelihood of DVT based on clinical assessment. It can help cent surgery, trauma, severe burns, and pregnancy (specificity,
determine the pre-­test probability of DVT when it is estimated 42–52%).16,17 Therefore, a negative D-­dimer result helps exclude
by an experienced physician.12,13 However, validated clinical de- DVT, particularly when the clinical probability is low, and a pos-
cision rules are more reliable.14 itive D-­dimer result requires imaging to confirm DVT.

1
Fiona Stanley Hospital, Perth, WA. 2 PathWest Laboratory Medicine, Perth, WA. 3 Population Health Research Institute, Hamilton, Canada. 4 Hamilton Health Sciences, Hamilton, Canada.
516 5
St. Joseph’s Healthcare Hamilton, McMaster University, Hamilton, Canada. 6 University of Western Australia, Perth, WA. graeme.hankey@uwa.edu.au ▪ doi: 10.5694/mja2.50201
Podcast with Paul Kruger available at https://www.mja.com.au/podcasts
 Narrative review

1  The National Health and Medical Research Council levels of 2  Diagnosing first deep vein thrombosis (DVT) presenting in an
evidence10 outpatient or in primary care
Evidence
Component base Definition

A Excellent One or more level I studies with a

low risk of bias or several level II
studies with a low risk of bias

B Good One or two level II studies with a low

risk of bias or a systematic review
or several level III studies with a low
risk of bias

C Satisfactory One or two level III studies with a

low risk of bias, or level I or II studies
with a moderate risk of bias

D Poor Level IV studies, or level I to III stud-

ies or systematic reviews with a high
risk of bias

D-­dimer testing may also be used to predict the risk of recurrent

VTE after ceasing anticoagulation, but is not recommended as CUS = compression ultrasound. ◆
a screening test for subclinical disease recurrence or to monitor
response to anticoagulation.18

Diagnostic imaging probability of DVT because a negative D-­dimer result does not
exclude DVT with sufficient certainty in such patients, and an
Venous compression ultrasound (CUS) is the first-­line imaging
increased D-­dimer level is not specific for DVT.18,23
test for suspected DVT.19 There are two acceptable strategies. The
first is CUS limited to the proximal leg (thigh and popliteal re-
Investigating for underlying risk factors
gion) to diagnose proximal DVT, and to repeat one week later to
assess for distal DVT extending proximally. The second is CUS Risk factors for DVT (Box 3) determine the risk of recurrent
of the whole leg which, if negative, avoids the need for a repeat DVT.25
limited CUS, but may diagnose distal DVTs that may not require Unprovoked VTE requires assessment for occult cancer, present
anticoagulation.20 The risk of missing a DVT in the first 3 months in up to 10% of patients.26 However, extensive cancer screening
after a negative whole leg CUS is less than 2%.21 Compared with with computed tomography of the body or tumour markers
venography, CUS has a sensitivity of 93.8% (95% CI, 92.0–95.3) is not recommended, unless symptoms of possible cancer are
and specificity of 97.8% (95% CI, 97.0–98.4) for proximal DVT.22 present.27

Using an integrated approach to diagnosis of first deep vein Testing for hereditary thrombophilia may identify predisposi-
thrombosis tion to the development of VTE, guide testing of family members,
and determine the need for long term prophylactic anticoagula-
The diagnosis of DVT requires an integrated approach because
tion. However, thrombophilia testing is not indicated routinely.
the clinical presentation, clinical decision rule or investigations
Selecting who to test requires consideration because the results
used in isolation may be insufficient to confirm or exclude DVT
will not change management in most patients with VTE, as the
(Box 2). Alternative algorithms have been presented by the
most common thrombophilias (factor V Leiden and prothrom-
American Society of Hematology and THANZ.9,14
bin gene mutations) are not strong predictors of recurrent VTE.28
A low to moderate pre-­test probability by gestalt, or “unlikely” Testing for thrombophilia can be considered in patients with un-
DVT (Wells rule ≤ 1), indicates the need for D-­dimer measurement. provoked VTE who are aged less than 50 years, or who have a
D-­dimer has a negative predictive value of 99.1% (95% CI, 96.7– strong family history of VTE, or who have recurrent venous or
99.9) in populations with a 16% prevalence of DVT.23 Therefore, a arterial thrombosis.29,30 Thrombophilia testing should not be
normal D-­dimer level in patients with “unlikely” DVT effectively performed in patients with VTE provoked by surgery or major
excludes DVT (evidence level A; Box 1). An increased D-­dimer trauma (evidence level B) because the risk of recurrent VTE is low.
level infers that DVT may be present (along with other alternative
Testing for the antiphospholipid syndrome — an acquired
MJA 210 (11) ▪ 17 June 2019

diagnoses) and indicates the need for a CUS to confirm or exclude

thrombophilia — is indicated when patients develop arterial or
DVT. A CUS that is positive for proximal DVT confirms DVT and
venous thrombosis in the setting of thrombocytopenia, haemo-
the need to initiate anticoagulant therapy, whereas anticoagulant
lytic anaemia, livedo reticularis or cognitive dysfunction in the
therapy can be withheld with a negative CUS. Ideally, a negative
absence of a stroke.31 Patients with abdominal (portal or hepatic
above-­knee CUS should be repeated one week later to exclude
vein) thrombosis may have an underlying myeloproliferative
the presence of a distal DVT that may have extended proximally.
disorder, and Janus kinase 2 (JAK2) V617F mutation testing is
Alternatively, a whole-­leg CUS may be performed and, if negative
recommended in patients without cirrhosis or malignancy.32
for DVT, does not need to be repeated (evidence level A).24
When DVT occurs in the setting of pancytopenia or haemolytic
A high pre-­test probability by gestalt, or “likely” DVT (Wells anaemia, testing for paroxysmal nocturnal haemoglobinuria
rule ≥ 2), indicates CUS, without the need for D-­dimer testing. should be considered, especially if the DVT is in an unusual 517
D-­dimer should not be measured in patients with a high pre-­test ­location (eg, splanchnic veins or cerebral sinuses).33,34
 Narrative review

3  Risk factors for venous thromboembolism* 25

VTE risk factor category Examples

Transient • Major: surgery with general anaesthesia > 30 minutes, confined to bed in hospital ≥ 3 days with an
acute illness, or caesarean section
• Minor: surgery with general anaesthesia < 30 minutes, admission to hospital < 3 days with an acute
illness, oestrogen therapy, pregnancy, confined to bed out of hospital for ≥ 3 days with an acute illness,
leg injury with reduced mobility

Permanent/persistent • Active cancer

• Chronic inflammation (eg, inflammatory bowel disease)
• Chronic autoimmune disease
• Chronic infections

Unprovoked • No transient or permanent/persistent factors

Non-­environmental • Male
• Hereditary thrombophilia (eg, protein C deficiency, protein S deficiency, antithrombin deficiency, factor
V Leiden mutation, prothrombin gene mutation)
• Older age

* Environmental (or acquired) risk factors for venous thromboembolism (VTE) may be transient or persistent. A transient risk factor is one that resolves after it has provoked the VTE.
Resolution of the transient risk factor should be confirmed before stopping anticoagulation therapy. A permanent/persistent risk factor is one that is still present after it provokes the VTE. A
VTE that occurs without transient or permanent/persistent risk factors is considered unprovoked. Non-­environmental (or intrinsic) risk factors do not influence whether a VTE is considered
provoked or unprovoked but may influence the risk of recurrence. ◆

exceed 100 mg daily, but, otherwise, it should be avoided during

Investigating patients with deep vein thrombosis for anticoagulant therapy.37
simultaneous pulmonary embolism
About 56% of patients with proximal DVT have pulmonary em- Commencing anticoagulation while waiting for test results is
bolism.35 Chest imaging is not needed routinely because anti- reasonable if the suspicion of DVT is “likely”. Not commencing
coagulation is required regardless, but it may be justified if the anticoagulation while waiting for results is reasonable for pa-
patient has significant symptoms of pulmonary embolism, as tients at increased risk of bleeding or if the suspicion of DVT
this may change management (eg, thrombolysis for clinically is “unlikely”, provided the results will be available within 24
massive pulmonary embolism) and prognosis (eg, long term risk hours.36
of chronic thromboembolic pulmonary hypertension).8
Anticoagulant agents
Options for the initial treatment of VTE include a DOAC (apixa-
Management ban or rivaroxaban), initial parenteral anticoagulation followed
by a DOAC (dabigatran or edoxaban, because initial parenteral
Anticoagulation
therapy was administered in the randomised phase 3 trials of da-
Anticoagulation is the mainstay of treatment for VTE; it aims to bigatran and edoxaban) or initial parenteral anticoagulation over-
reduce mortality, thrombus extension, recurrence, and the risk lapped by warfarin and continued for at least 5 days and until the
of PTS (after DVT) and chronic thromboembolic pulmonary hy- international normalised ratio (INR) is more than 2.0 on two oc-
pertension (after pulmonary embolism). The phases of antico- casions 24 hours apart (evidence level A). The DOACs — compris-
agulation treatment are “initial” (first week after VTE diagnosis), ing the direct thrombin inhibitor dabigatran and the factor Xa
“long term” (first 3 months after diagnosis) and “extended” (no inhibitors rivaroxaban, apixaban and edoxaban — are as effective
scheduled stop date) (Box 4).36 as and safer than warfarin (INR, 2.0–3.0) for the treatment of VTE,
Clinically significant bleeding is a contraindication to anticoag- whereas betrixaban has not been assessed for VTE treatment and
ulation. Relative contraindications include recent bleeding (eg, is indicated only for VTE prophylaxis in hospitalised medical pa-
gastrointestinal bleeding within 2 weeks, intracranial bleeding tients.38,39 Three DOACs — dabigatran, rivaroxaban and apixa-
within 3 months), recent trauma, known bleeding disorder, se- ban — are approved by the Pharmaceutical Benefits Scheme for
vere thrombocytopenia (platelet count < 75 × 109/L), endocardi- the treatment of VTE. Despite the DOACs being classified col-
tis and uncontrolled hypertension. lectively, each has a unique molecular structure and they should
therefore be considered as individual anticoagulants (Box 5).40–43
Risk factors for bleeding include age over 65 years, previous Warfarin is associated with a slightly higher bleeding risk than
bleeding, cancer, metastatic cancer, renal failure, liver failure, DOACs, with an absolute risk increase for major bleeding of
MJA 210 (11) ▪ 17 June 2019

thrombocytopenia, previous stroke, diabetes, anaemia, anti- about 1%, and requires routine coagulation monitoring.36,38,44
platelet therapy, poor anticoagulation control (for vitamin K an-
tagonists), comorbidity and reduced functional capacity, recent Anticoagulant selection
surgery, frequent falls and alcohol misuse. The risk of bleeding
The choice of anticoagulant should consider medical issues such
can be estimated as low, intermediate or high if none, one, or
as efficacy, safety, renal and hepatic function, and concurrent
two or more of these factors are present, respectively.36 Long
medications. In addition, practical issues such as availability, fa-
term concomitant use of non-­steroidal anti-­inflammatory drugs
miliarity of use, patient preference, and cost should be considered.
should be avoided if possible, but short (1–2 weeks) courses of
treatment can be used, for example, in patients with an inflamed DOACs are an ideal first-­line anticoagulant for the treatment of
leg or superimposed superficial phlebitis. For patients who re- VTE in an uncomplicated patient, have advantages over vitamin
518
quire aspirin for cardiovascular prevention, the dose should not K antagonists (Box 6),45 and have few drug–drug interactions
 Narrative review
DVT may be considered provoked if a transient or permanent or
4  Anticoagulants for venous thromboembolism (VTE)36 persistent environmental risk factor is present, or unprovoked if
Phase
no such risk factor is present (Box 3). Risk factors for VTE inform
the risk of recurrent VTE. For example, in patients with VTE
Agent and VTE treatment dose Initial Long term Extended who are treated with 3–6 months of anticoagulation, stopping
Unfractionated heparin 80 IU/ ●
anticoagulation is associated with a one-­year risk of recurrence
kg intravenous bolus, then 18 IU/ of about 1–3% when the initial VTE occurred in the context of
kg per hour a major transient risk factor, about 10% when the event is un-
intravenous infusion, target aPTT provoked, and more than 10% when the event occurs in patients
is hospital-­specific
with active cancer.25 In patients with thrombophilia, factors
Enoxaparin 1.5 mg/kg ● ● ● such as the factor V Leiden and prothrombin gene mutations
subcutaneous daily, or 1.0 mg/kg (cancer) (cancer) are weak determinants of disease recurrence, whereas less com-
subcutaneous twice daily
mon factors such as inherited deficiencies of protein C, protein S
Dalteparin 100 IU/kg subcutane- ● ● ● and antithrombin and the antiphospholipid antibody syndrome
ous twice daily, or for patients with (cancer) (cancer) are stronger predictors of recurrent VTE, for which the THANZ
cancer 200 IU/kg subcutaneous
guidelines suggest extended anticoagulant therapy.29
daily (maximum 18 000 IU/day) for
30 days, 150 IU/kg thereafter Six weeks of anticoagulation are recommended for treatment of
Nadroparin 86 anti-­Xa IU/kg body ● distal DVT caused by a major transient risk factor that is no lon-
weight subcutaneous twice daily ger present (evidence level B). Three months of anticoagulation
Apixaban 10 mg oral twice daily for ● ● ●
are recommended for the treatment of proximal DVT provoked
7 days, then 5 mg twice daily. For by surgery or trauma (evidence level A), proximal DVT provoked
extended treatment, decrease to by a non-­surgical transient risk factor, unprovoked isolated dis-
2.5 mg twice daily tal DVT (evidence level B), and for unprovoked DVT when the
Rivaroxaban 15 mg oral twice daily ● ● ● bleeding risk is high. A minimum of 3 months of anticoagula-
for 21 days, then 20 mg daily. For tion, followed by re-­evaluation of the risk–benefit ratio, is indi-
extended treatment, decrease to cated for unprovoked proximal DVT (evidence level A). At least
10 mg daily
6 months of anticoagulation are recommended for DVT that is
Dabigatran* 150 mg oral twice ● ● provoked by active cancer (evidence level A). Extended anticoag-
daily. Decrease to 110 mg twice ulation is recommended for a second or unprovoked DVT, if risk
daily if age > 75 years or CrCl
factors such as active cancer persist, or for unprovoked proximal
30–49 mL/min
DVT when the bleeding risk is low.44 Patients receiving extended
Warfarin* once daily, oral adminis- ● ● anticoagulation should be followed up at least once per year to
tration; target INR 2.0–3.0 re-­evaluate their individual risk of thrombosis and bleeding,
Aspirin† 100 mg daily (after anti- ● monitor for adverse effects from the anticoagulant, and detect
coagulation ceased) changes that may affect the half-­life of the anticoagulant (eg,
aPTT = activated partial thromboplastin time; CrCl = creatinine clearance; INR = interna- renal impairment). DOACs are preferred over warfarin for long
tional normalised ratio. * Initial parenteral anticoagulation (unfractionated heparin or low term and extended anticoagulation therapy, provided there are
molecular weight heparin) is required for dabigatran for a minimum of 5 days, and for
warfarin until the INR is 2.0–3.0. † For patients with first unprovoked VTE who cannot
no contraindications (evidence level A), but warfarin is a reason-
access or tolerate ongoing anticoagulation but require reduction of thrombosis risk. ◆ able alternative when INR monitoring is feasible and acquisition
costs of DOACs are an issue. After long term treatment of VTE,
extended treatment with low dose apixaban (2.5 mg twice daily)
46–49 or low dose rivaroxaban (10 mg once daily) is effective at reduc-
(Box 7). In patients treated with dabigatran, idarucizumab
ing the risk of recurrent VTE compared with placebo or aspirin,
can reverse anticoagulation in emergency situations (eg, life-­
50 respectively, without increasing the rate of major bleeding.54,55
threatening bleeding, urgent surgery). In patients treated with
rivaroxaban or apixaban, andexanet alfa has been approved in
Inferior vena cava filter
the United States and Europe for reversing the anticoagulant ef-
fect but not yet in Australia. 51 Placement of an inferior vena cava (IVC) filter should be con-
sidered in specific clinical circumstances. Among 2055 patients
DOAC treatment is not recommended in pregnant women and is with acute proximal DVT and a contraindication to anticoagula-
contraindicated in patients with severe renal impairment (creat- tion, IVC filter insertion reduced the risk of subsequent pulmo-
inine clearance [CrCl] < 30 mL/min for edoxaban, rivaroxaban nary embolism by 50% compared with no filter.56 However, IVC
15 mg and 20 mg tablets, and dabigatran; or CrCl < 25 mL/min filters are associated with a 70% increased risk of subsequent
for apixaban; or CrCl < 15 mL/min for rivaroxaban 10 mg tab- DVT when compared with no IVC filter insertion, and carry
MJA 210 (11) ▪ 17 June 2019

lets), severe hepatic impairment (Child–Pugh score C), mechani- unique risks such as filter thrombosis (about 2% of cases), migra-
cal heart valves, and concomitant administration of drug classes tion, and penetration of the wall of the IVC. In a cohort study of
that are strong inhibitors of CYP3A4 and P-­glycoprotein.52,53 126 030 patients with VTE and a contraindication to anticoagula-
When treatment with a DOAC is not appropriate, anticoagula- tion, 30-­day mortality was significantly higher in patients who
tion with intravenous unfractionated heparin, low molecular had an IVC filter inserted compared with no IVC filter (hazard
weight heparin (LMWH) or warfarin are alternatives. ratio [HR], 1.18; 95% CI, 1.13–1.22; P < 0.001).57 IVC filters should
only be considered in patients with an absolute contraindication
Duration of anticoagulation to anticoagulation or selected patients who develop recurrent
The duration of the anticoagulation for DVT depends on the risk pulmonary embolism despite anticoagulation and have signifi-
of recurrence, which is determined by whether the DVT is pro- cant residual DVT (evidence level C).44 Massive pulmonary em-
519
voked by a transient or ongoing risk factor, or unprovoked. A bolism is not an indication for an IVC filter.56,58 The IVC filter
 Narrative review

5  Efficacy of direct oral anticoagulants versus warfarin (international normalised ratio, 2.0–3.0) for symptomatic venous thromboem-
bolism (VTE)

RE- ­COVER40 EINSTEIN-­DVT41 AMPLIFY42 Hokusai-­V TE43

Treatment Dabigatran* (n = 1274) Rivaroxaban* (n = 1731) Apixaban (n = 2691) Edoxaban* (n = 4118)

v warfarin* (n = 1265) v warfarin* (n = 1718) v warfarin* (n = 2704) v warfarin* (n = 4122)

Index event ■ DVT 69% ■ DVT 99% ■ DVT 65% ■ DVT 60%
■ PE 21% ■ PE 1% ■ PE 25% ■ PE 40%
■ PE + DVT 10% ■ PE + DVT 9%

Outcomes HR (95% CI) HR (95% CI) RR (95% CI) HR (95% CI)

† ‡
Primary efficacy 1.10 (0.65–1.84) 0.84 (0.60–1.18) 0.89 (0.70–1.13)‡

Recurrent VTE 0.68 (0.44–1.04)‡

Major bleeding 0.82 (0.45–1.48) 0.65 (0.33–1.30) 0.31 (0.17–0.55)‡ 0.84 (0.59–1.21)

All deaths 0.98 (0.53–1.79) 0.67 (0.44–1.02) 0.79 (0.53–1.19)

AMPLIFY  =  Apixaban for the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis as First-­line Therapy; DVT  =  deep vein thrombosis; EINSTEIN-­DVT  =  Oral Direct
Factor Xa Inhibitor Rivaroxaban in Patients with Acute Symptomatic Deep Vein Thrombosis without Symptomatic Pulmonary Embolism; Hokusai-­V TE  =  Edoxaban versus Warfarin for
the Treatment of Symptomatic Venous Thromboembolism; HR = hazard ratio; RE-­COVER = Efficacy and Safety of Dabigatran Compared with Warfarin for 6-­month Treatment of Acute
Symptomatic Venous Thromboembolism; RR = relative risk. * Initial parenteral anticoagulation (heparin or low molecular weight heparin) was administered. † Recurrent symptomatic VTE
or VTE-­related death. ‡ P < 0.05. ◆

6  Key factors that influence the choice of anticoagulant for venous thromboembolism (VTE)*45

Routine Daily Adverse Reversal

Anticoagulant Indications monitoring injections effects Contraindications† agent Cost

Dabigatran • DVT No No Bleeding,‡ CrCl < 30 mL/min, severe Idarucizumab $$$

• PE dyspepsia ­hepatic impairment, pregnancy,
breastfeeding

Rivaroxaban • DVT No No Bleeding‡ CrCl < 30 mL/min, severe he- $$$

• PE patic impairment, pregnancy,
breastfeeding

Apixaban • DVT No No Bleeding‡ CrCl < 25 mL/min, severe he- $$$

• PE patic impairment, pregnancy,
breastfeeding

Enoxaparin • DVT No Yes Bleeding Heparin-­induced thrombocytope- $$$

• PE nia within previous 100 days
• Cancer-associated
VTE

Dalteparin • DVT No Yes Bleeding Heparin-­induced $$$

• PE thrombocytopenia

Warfarin • DVT Yes No Bleeding, Intracranial haemorrhage, skin Vitamin K, $

• PE intracranial necrosis, pregnancy, breastfeeding prothrombin
haemor- complex
rhage, not concentrate
safe in
pregnancy

Unfractionated • DVT Yes Yes Heparin-­induced Protamine $

heparin • PE thrombocytopenia
• Cancer-associated
VTE

CrCl = creatinine clearance; DVT = deep vein thrombosis; PE = pulmonary embolism. * Patients with acute VTE should be evaluated for treatment with a direct oral anticoagulant (DOAC). In
patients who are eligible for treatment with a DOAC, there is no evidence to recommend one agent over another because the DOACs have not been compared directly. The choice of DOAC
MJA 210 (11) ▪ 17 June 2019

is guided by considering renal function, whether initial parenteral anticoagulation (with dabigatran) is cumbersome, and whether once per day or twice per day dosing is preferred. † Active
bleeding and known hypersensitivity are contraindications for all anticoagulants. ‡ Including upper gastrointestinal tract bleeding. ◆

should be removed preferably within 3 weeks of placement and anticoagulation alone in patients with acute proximal leg DVT
when it is safe to resume anticoagulation. showed no reduction in the risk of PTS and increased bleeding
with dual therapy.59 Patients with recent (<  1  week) extensive,
Thrombolysis typically iliofemoral, DVT or with phlegmasia cerulea dolens
Catheter-­directed thrombolysis involves the percutaneous in- and at low bleeding risk were poorly represented in this trial
sertion of a catheter and infusion of a thrombolytic — typically and may yet benefit from catheter-­directed thrombolysis (evi-
520 recombinant tissue plasminogen activator (tPA) — directly to dence level C).60 In contrast to leg DVT, there have been no ran-
the DVT. A randomised trial of anticoagulation plus tPA versus domised trials of thrombolysis for treatment of arm DVT.61
 Narrative review

7  Direct oral anticoagulant (DOAC) interaction with other medicines

DOAC Contraindicated Caution

46
Rivaroxaban • Antifungals (ketoconazole, itraconazole, voriconazole, • Antifungals (fluconazole)
posaconazole) • Antibiotics (clarithromycin, erythromycin, rifampicin)
• HIV protease inhibitors (ritonavir) • Antiarrhythmics (amiodarone, quinidine, diltiazem, verapamil)
• Anticonvulsants (phenytoin, carbamazepine, phenobarbitone)
• Other (cyclosporine, St John’s Wort)
• Co-administration with other anticoagulants or antiplatelets

Apixaban47 • Antifungals (ketoconazole, itraconazole, voriconazole, • Antibiotics (clarithromycin, rifampicin)

posaconazole) • Anticonvulsants (phenytoin, carbamazepine, phenobarbitone)
• HIV protease inhibitors (ritonavir) • Antiarrhythmics (diltiazem, amiodarone, quinidine, verapamil)
• Any other anticoagulant • Non-steroidal anti-inflammatory drugs (naproxen)

Dabigatran48 • Antimicrobials (rifampicin, tipranavir) • Co-administration with other anticoagulants and antiplatelets
• Anticonvulsants (carbamazepine, phenytoin,
fosphenytoin)
• Other (dexamethasone, St John’s Wort)

Edoxaban49 • Rifampicin • Antifungals (ketoconazole)

• Antibiotics (erythromycin)
• Antiarrhythmics (quinidine, dronedarone)
• HIV protease inhibitors (darunavir/ritonavir, lopinavir/ritonavir)
• Non-steroidal anti-inflammatory drugs (naproxen)
• Other (cyclosporine)
• Co-administration with other anticoagulants and antiplatelets

HIV = human immunodeficiency virus. ◆

Surgical thrombus removal 0.09–2.64).54 In another similar population, extended antico-

agulation with rivaroxaban was more effective than aspirin in
Surgical removal of DVT does not have a proven role. Some sug-
reducing recurrent VTE (HR, 0.34; 95% CI, 0.20–0.59, for 20 mg
gest that venous thrombectomy should only be considered in
daily dose; HR, 0.26; 95%  CI, 0.14–0.47, for 10  mg daily dose v
patients with impending venous gangrene despite optimal an-
aspirin), without a significant increase in bleeding rates (major
ticoagulation and all of the following: catheter-­directed throm-
bleeding 0.5% with rivaroxaban 20  mg, 0.4% with rivaroxaban
bolysis not available, iliofemoral DVT, symptoms for less than 7
10 mg, and 0.3% with aspirin 100 mg daily).55
days, good functional status, life expectancy greater than one
year, and availability of appropriate resources and expertise.36
Special circumstances affecting the diagnosis and
Compression stockings management of deep vein thrombosis
Pregnancy
Current evidence suggests a beneficial effect of early application
of elastic compression stockings on PTS and residual vein oc- Pregnant women may not be assessed accurately using the Wells
clusion (evidence level C). In the IDEAL DVT study, compres- rule for DVT because the rule was derived from a non-­pregnant
sion stockings worn for at least a minimum of 6 months until population. The LEFt rule is an alternative clinical prediction
the Villalta score decreased to 4 or less on two consecutive read- rule that assigns one point each for symptoms in the left leg, calf
ings, compared with 2 years, were non-­inferior for preventing circumference difference of 2 cm or more, and first trimester of
PTS in patients with acute proximal DVT (29% v 28%; odds ratio pregnancy.65 A LEFt score of zero points is accurate to rule out
[OR], 1.06; 95% CI, 0.78–1.44).62 In a pre-­specified substudy of the DVT in pregnant women.66 D-­dimer level is less likely to rule out
IDEAL DVT study, acute compression of the leg within 24 hours DVT in pregnancy because it steadily increases until delivery;
of DVT diagnosis, compared with no compression, was associ- therefore, reports conflict over whether to perform this test for
ated with a decrease in residual vein obstruction (46% v 66%; OR, suspected VTE in pregnancy.18,66 When DVT is confirmed, the
0.46; 95%  CI, 0.27–0.80) and PTS (46% v 54%; OR, 0.65; 95%  CI, most appropriate anticoagulation is LMWH (evidence level A).
0.46–0.92).63 Warfarin use during pregnancy is associated with an increased
risk for fetal embryopathy, especially when used during weeks
Secondary prevention of venous thromboembolism 6–12 of gestation.67 DOACs have been used in pregnancy, but
Aspirin 100 mg daily is reasonable to decrease the risk of recur- experience is limited.68 As DOACs are small molecules that cross
rent VTE in patients who have completed anticoagulation treat- the placenta, there is potential for adverse effects on the fetus.
MJA 210 (11) ▪ 17 June 2019

ment for a first unprovoked DVT or pulmonary embolism, and

in whom ongoing anticoagulation is not appropriate or cannot Cancer
be accessed.64 Since the introduction of DOACs, new second- Active cancer may be associated with an increased D-­dimer level
ary prevention strategies have been tested. In patients with VTE even if DVT is not present, which reduces the negative predic-
who had completed 6–12 months of anticoagulant therapy, and tive value for DVT.18 Previously, LMWH has been recommended
in whom there was clinical equipoise regarding the continua- for treatment of DVT for patients with cancer because, compared
tion or cessation of anticoagulant therapy, extended anticoagula- with warfarin, the rate of recurrent VTE is lower and the rate
tion with low dose apixaban 2.5 mg twice daily for a further 12 of bleeding is similar.69 The optimal duration of anticoagula-
months was more effective than placebo in reducing recurrent tion for cancer-­associated VTE has not been formally assessed
VTE or death from any cause (relative risk [RR], 0.33; 95%  CI, beyond 6 months. Continuing anticoagulation for longer than 6 521
0.22–0.48) without increasing major bleeding (RR, 0.49; 95% CI, months is indicated if the cancer is still active or treatment with
 Narrative review
chemotherapy, radiotherapy or hormonal therapy is ongoing.27,70 patients with high risk of recurrence (eg, unprovoked proximal
Two DOACs have recently been compared with LMWH for cancer-­ DVT). When VTE recurs during anticoagulation treatment, the
related VTE. Edoxaban (after 5 days of initial LMWH), compared patient should be evaluated for suboptimal anticoagulation ther-
with LMWH (dalteparin), was non-­inferior for the composite out- apy (eg, incorrect dose, poor adherence) and the emergence of
come of recurrent VTE or major bleeding. The rate of recurrent conditions that increase the risk of recurrent VTE (eg, cancer).75
VTE was not different (7.9% v 11.3%; HR, 0.71; 95% CI, 0.48–1.06),
but the risk of major bleeding was higher with edoxaban (6.9% Antiphospholipid syndrome
v 4.0%; HR, 1.77; 95% CI, 1.03–3.04) and there was no difference Patients with antiphospholipid syndrome should be anticoagu-
in mortality.71 Rivaroxaban (no initial LMWH), compared with lated with warfarin.31 In high risk patients with antiphospho-
dalteparin, decreased the rate of recurrent VTE (HR, 0.43; 95% CI, lipid syndrome, rivaroxaban treatment was associated with no
0.19–0.99) and increased the risk of clinically relevant non-­major benefit and increased risk compared with warfarin (evidence
bleeding (HR, 3.76; 95% CI, 1.63–8.69), but the risk of major bleed- level C).76 Further studies are needed to assess the safety of
ing was not significantly different (HR, 1.83; 95% CI, 0.68–4.96).72 DOACs in selected, lower risk patients with antiphospholipid
In both trials, the increased rate of bleeding with DOACs was syndrome.
mainly due to the higher rate of upper gastrointestinal bleeding
in patients enrolled with gastrointestinal cancer. These data sup- Superficial vein thrombosis
port rivaroxaban and edoxaban as effective oral treatment op- Superficial vein thrombosis manifests as thrombosis of a super-
tions for patients with VTE and cancer (evidence level B). ficial venous system and is associated with a low incidence of
proximal DVT and pulmonary embolism. Anticoagulation with
Distal deep vein thrombosis a prophylactic dose of LMWH or fondaparinux for 45 days is
Isolated distal (calf) DVTs have a lower risk of extension than recommended in patients with leg superficial vein thrombo-
proximal DVTs and do not always require anticoagulation. sis greater than 5 cm in length, severe symptoms, involvement
About 15% of isolated distal DVTs will extend to the proximal of the greater saphenous vein, history of VTE or superficial
veins if not treated, usually in less than 2 weeks.73 Treatment vein thrombosis, active cancer, and recent surgery (evidence
with anticoagulation for 3 months may be considered for patients level C). Patients with superficial vein thrombosis above the
with distal DVT who have a significant symptom burden, or if knee should have a CUS to investigate for DVT. Non-­steroidal
risk factors for extension are present (eg, thrombosis > 5 cm in anti-­inflammatories can alleviate pain in patients who are not
length, > 7 mm maximum diameter, involving multiple veins), anticoagulated.36
the DVT is unprovoked, there is a history of active cancer or pre-
vious VTE, or the patient is currently admitted to hospital. If the Conclusion
patient is asymptomatic and does not initially receive anticoagu-
lation, it is suggested to repeat the CUS after 1–2 weeks to detect The diagnosis of DVT requires a high index of suspicion because
possible proximal extension.73 symptoms and signs are often non-­ specific. Anticoagulation
continues to be the cornerstone of therapy. The optimal antico-
Recurrent deep vein thrombosis agulant and duration of therapy are determined by the clinical
Recurrent DVT is more difficult to diagnose than first DVT be- assessment.
cause the features of the initial episode of DVT may persist on
Competing interests: No relevant disclosures.
CUS.74 Diagnosis of recurrent DVT may be assisted by compar-
ing the CUS with a previous one at the end of treatment of the Provenance: Commissioned; externally peer reviewed. ■
first DVT. Hence, repeating the CUS at the end of anticoagula-
tion, although not performed routinely,24 can be valuable in © 2019 AMPCo Pty Ltd

1 Heit JA, Spencer FA, White RH. The 6 Iorio A, Kearon C, Filippucci E, et al. Risk of Canberra: NHMRC, 1999. https​: //nhmrc.gov.au/
epidemiology of venous thromboembolism. recurrence after a first episode of symptomatic about-us/publi​c atio​ns/guide-devel​opment-evalu​
J Thromb Thrombolysis 2016; 41: 3–14. venous thromboembolism provoked by a ation-and-imple​menta​tion-clini​c al-pract​ice-
2 Spencer FA, Gore JM, Lessard D, et al. Patient transient risk factor: a systematic review. Arch guide​lines​ (viewed Feb 2019).
outcomes after deep vein thrombosis and Intern Med 2010; 170: 1710–1716.
11 Divittorio R, Bluth EI Sullivan MA. Deep vein
pulmonary embolism: the Worcester Venous 7 Wallace R, Anderson MA, See K, et al. Venous thrombosis: diagnosis of a comon clinical
Thromboembolism Study. Arch Intern Med thromboembolism management practices and problem. Ochsner J 2002; 4: 14–17.
2008; 168: 425–430. knowledge of guidelines: a survey of Australian
12 Sanders S, Doust J, Glasziou P. A systematic
3 Galanaud JP, Monreal M, Kahn SR. Epidemiology haematologists and respiratory physicians.
review of studies comparing diagnostic clinical
of the post-­thrombotic syndrome. Thromb Res Intern Med J 2017; 47: 436–446.
prediction rules with clinical judgment. PLoS
2018; 164: 100–109. 8 Kruger PC, Eikelboom JW, Douketis JD, Hankey
One 2015; 10: e0128233.
4 Ende-Verhaar YM, Cannegieter SC, Vonk GJ. Pulmonary embolism: update on diagnosis
MJA 210 (11) ▪ 17 June 2019

and management. Med J Aust 2019. In press. 13 Geersing GJ, Janssen KJ, Oudega R, et al.
Noordegraaf A, et al. Incidence of chronic
Diagnostic classification in patients with
thromboembolic pulmonary hypertension after 9 Tran HA, Gibbs H, Merriman E, et al. New
suspected deep venous thrombosis: physicians’
acute pulmonary embolism: a contemporary guidelines from the Thrombosis and
judgement or a decision rule? Br J Gen Pract
view of the published literature. Eur Respir J Haemostasis Society of Australia and New
2010; 60: 742–748.
2017; 49. pii: 1601792. Zealand for the diagnosis and management of
venous thromboembolism. Med J Aust 2019; 14 Lim W, Le Gal G, Bates SM, et al. American
5 Prandoni P, Noventa F, Ghirarduzzi A, et al. The
210: 227–235. https​: //www.mja.com.au/journ​ Society of Hematology 2018 guidelines for
risk of recurrent venous thromboembolism
al/2019/210/5/new-guide​lines-throm​bosis-and- management of venous thromboembolism:
after discontinuing anticoagulation in patients
haemo​s tasis-socie​t y-austr​alia-and-new-zealand diagnosis of venous thromboembolism. Blood
with acute proximal deep vein thrombosis or
Adv 2018; 2: 3226–3256.
pulmonary embolism. A prospective cohort 10 National Health and Medical Research Council.
study in 1,626 patients. Haematologica 2007; A guide to the development, implementation 15 Geersing GJ, Zuithoff NP, Kearon C, et al.
522 92: 199–205. and evaluation of clinical practice guidelines. Exclusion of deep vein thrombosis using the
 Narrative review
Wells rule in clinically important subgroups: 3 3 Donadini MP, Ageno W. Unusual site thrombosis. 51 Heo YA. Andexanet alfa: first global approval.
individual patient data meta-­analysis. BMJ 2014; Semin Hematol 2011; 48: 264–270. Drugs 2018; 78: 1049–1055.
348: g1340. 3 4 Hill A, Kelly RJ, Hillmen P. Thrombosis in 5 2 Turpie AGG, Purdham D, Ciaccia A. Nonvitamin
16 Di Nisio M, Squizzato A, Rutjes AW, et al. paroxysmal nocturnal hemoglobinuria. Blood K antagonist oral anticoagulant use in patients
Diagnostic accuracy of D-­dimer test for 2013; 121: 4985–4996; quiz 5105. with renal impairment. Ther Adv Cardiovasc Dis
exclusion of venous thromboembolism: a 35 Hirsh J, Hoak J. Management of deep vein 2017; 11: 243–256.
systematic review. J Thromb Haemost 2007; 5: thrombosis and pulmonary embolism. A 5 3 Burnett AE, Mahan CE, Vazquez SR, et al.
296–304. statement for healthcare professionals. Council Guidance for the practical management of
17 Harper PL, Theakston E, Ahmed J, Ockelford on Thrombosis (in consultation with the Council the direct oral anticoagulants (DOACs) in VTE
P. D-­dimer concentration increases with age on Cardiovascular Radiology), American Heart treatment. J Thromb Thrombolysis 2016; 41:
reducing the clinical value of the D-­dimer assay Association. Circulation 1996; 93: 2212–2245. 206–232.
in the elderly. Intern Med J 2007; 37: 607–613. 36 Kearon C, Akl EA, Comerota AJ, et al. 5 4 Agnelli G, Buller HR, Cohen A, et al.
18 Adam SS, Key NS, Greenberg CS. D-­dimer Antithrombotic therapy for VTE disease: Apixaban for extended treatment of venous
antigen: current concepts and future prospects. antithrombotic therapy and prevention of thromboembolism. N Engl J Med 2013; 368:
Blood 2009; 113: 2878–2887. thrombosis, 9th ed, American College of Chest 699–708.
Physicians evidence-­based clinical practice 5 5 Weitz JI, Lensing AWA, Prins MH, et al.
19 Karande GY, Hedgire SS, Sanchez Y, et al.
guidelines. Chest . 2012; 141: e419S–e496S. Rivaroxaban or Aspirin for Extended Treatment
Advanced imaging in acute and chronic deep
vein thrombosis. Cardiovasc Diagn Ther 2016; 6: 3 7 Weitz JI, Jaffer IH, Fredenburgh JC. Recent of Venous Thromboembolism. N Engl J Med 2017;
493–507. advances in the treatment of venous 376: 1211–1222.
thromboembolism in the era of the direct oral 56 Bikdeli B, Chatterjee S, Desai NR, et al. Inferior
20 Bernardi E, Camporese G, Buller HR, et al. Serial anticoagulants. F1000Res 2017; 6: 985.
2-­point ultrasonography plus D-­dimer vs whole-­ Vena cava filters to prevent pulmonary
leg color-­coded Doppler ultrasonography for 3 8 van Es N, Coppens M, Schulman S, et al. Direct embolism: systematic review and meta-­analysis.
diagnosing suspected symptomatic deep vein oral anticoagulants compared with vitamin K J Am Coll Cardiol 2017; 70: 1587–1597.
thrombosis: a randomized controlled trial. JAMA antagonists for acute venous thromboembolism: 5 7 Turner TE, Saeed MJ, Novak E, Brown DL.
2008; 300: 1653–1659. evidence from phase 3 trials. Blood 2014; 124: Association of inferior vena cava filter
1968–1975. placement for venous thromboembolic disease
21 Johnson SA, Stevens SM, Woller SC, et al. Risk of
39 Cohen AT. Extended thromboprophylaxis with and a contraindication to anticoagulation with
deep vein thrombosis following a single negative
betrixaban: a new standard for acute medically 30-­day mortality. JAMA Network Open 2018; 1:
whole-­leg compression ultrasound: a systematic
ill patients. Eur Heart J Suppl 2018; 20 (Suppl): e180452.
review and meta-­analysis. JAMA 2010; 303:
E1–E2. 5 8 Caplin DM, Nikolic B, Kalva SP, et al. Quality
438–445.
4 0 Schulman S, Kearon C, Kakkar AK, et al. improvement guidelines for the performance
2 2 Goodacre S, Sampson F, Thomas S, et al.
Dabigatran versus warfarin in the treatment of of inferior vena cava filter placement for the
Systematic review and meta-­analysis of the
acute venous thromboembolism. N Engl J Med prevention of pulmonary embolism. J Vasc Interv
diagnostic accuracy of ultrasonography for deep
2009; 361: 2342–2352. Radiol 2011; 22: 1499–1506.
vein thrombosis. BMC Med Imaging 2005; 5: 6.
41 Bauersachs R, Berkowitz SD, Brenner B, et 59 Vedantham S, Goldhaber SZ, Julian JA, et
2 3 Wells PS, Anderson DR, Rodger M, et al.
al. Oral rivaroxaban for symptomatic venous al. Pharmacomechanical catheter-­directed
Evaluation of D-­dimer in the diagnosis of
thromboembolism. N Engl J Med 2010; 363: thrombolysis for deep-­vein thrombosis. N Engl J
suspected deep-­vein thrombosis. N Engl J Med
2499–2510. Med 2017; 377: 2240–2252.
2003; 349: 1227–1235.
42 Agnelli G, Buller HR, Cohen A, et al. Oral 60 Vedantham S, Piazza G, Sista AK, Goldenberg
24 Wells PS, Ihaddadene R, Reilly A, Forgie MA. apixaban for the treatment of acute venous NA. Guidance for the use of thrombolytic
Diagnosis of venous thromboembolism: 20 years thromboembolism. N Engl J Med 2013; 369: therapy for the treatment of venous
of progress. Ann Intern Med 2018; 168: 131–140. 799–808. thromboembolism. J Thromb Thrombolysis 2016;
2 5 Kearon C, Ageno W, Cannegieter SC, et al. 43 Buller HR, Decousus H, Grosso MA, et al. 41: 68–80.
Categorization of patients as having provoked or Edoxaban versus warfarin for the treatment of 61 Feinberg J, Nielsen EE, Jakobsen JC. Thrombolysis
unprovoked venous thromboembolism: guidance symptomatic venous thromboembolism. N Engl J for acute upper extremity deep vein thrombosis.
from the SSC of ISTH. J Thromb Haemost 2016; Med 2013; 369: 1406–1415. Cochrane Database Syst Rev 2017; (12):
14: 1480–1483.
4 4 Kearon C, Akl EA, Ornelas J, et al. Antithrombotic CD012175.
26 Gheshmy A, Carrier M. Venous Therapy for VTE Disease: CHEST Guideline and 62 Cate-Hoek T, Amin EE, Bourman AC, et al.
thromboembolism and occult cancer: impact on Expert Panel Report. Chest 2016; 149: 315–352. Individualised versus standard duration of
clinical practice. Thromb Res 2016; 140 (Suppl): elastic compression therapy for prevention
45 Eikelboom JW, Weitz JI. New anticoagulants.
S8–S11. of post-­thrombotic syndrome (IDEAL DVT):
Circulation 2010; 121: 1523–1532.
27 Khorana AA, Carrier M, Garcia DA, Lee AY. a multicentre, randomised, single-­blind,
46 Bayer Australia. Xarelto® (rivaroxaban) product
Guidance for the prevention and treatment of allocation-­concealed, non-­inferiority trial.
information. Sydney, NSW: Bayer, 2017. https​
cancer-­associated venous thromboembolism. Lancet Haematol 2018; 5: e25–e33.
://www.bayer.com.au/produ​c ts/produ​c t-detai​
J Thromb Thrombolysis 2016; 41: 81–91. 6 3 Amin EE, Bistervels IM, Meijer K, et al. Reduced
ls.php?id=559 (viewed Feb 2019).
28 Douketis J, Tosetto A, Marcucci M, et al. Patient-­ incidence of vein occlusion and postthrombotic
47 Pfizer Australia. Eliquis® (apixaban) product
level meta-­analysis: effect of measurement syndrome after immediate compression for deep
information. Sydney, NSW: Pfizer. http://www.
timing, threshold, and patient age on ability of vein thrombosis. Blood 2018; 132: 2298–2304.
medic​ines.org.au/files/​bqpel​iqu.pdf (viewed Feb
D-­dimer testing to assess recurrence risk after 2019). 6 4 Simes J, Becattini C, Agnelli G, et al. Aspirin
unprovoked venous thromboembolism. Ann ® for the prevention of recurrent venous
Intern Med 2010; 153: 523–531. 4 8 Boehringer Ingelheim. Pradaxa (dabigatran)
thromboembolism: the INSPIRE collaboration.
product information. Sydney, NSW: Boehringer
29 Stevens SM, Woller SC, Bauer KA, et al. Circulation 2014; 130: 1062–1071.
MJA 210 (11) ▪ 17 June 2019

Ingelheim, 2017. https​: //www.ebs.tga.gov.

Guidance for the evaluation and treatment of au/ebs/picmi/​picmi​repos​itory.nsf/pdf?OpenA​ 6 5 Chan WS, Lee A, Spencer FA, et al. Predicting
hereditary and acquired thrombophilia. J Thromb gent&id=CP-2009-PI-01177-3&d=20190​20710​ deep venous thrombosis in pregnancy: out in
Thrombolysis 2016; 41: 154–164. 16933​(viewed Feb 2019). “LEFt” field? Ann Intern Med 2009; 151: 85–92.
30 Connors JM. Thrombophilia testing and venous 49 Servier Canada. Lixiana® (edoxaban) product 66 Righini M, Jobic C, Boehlen F, et al. Predicting
thrombosis. N Engl J Med 2017; 377: 1177–1187. information. Laval, Quebec: Servier, 2017. https​ deep venous thrombosis in pregnancy: external
3 1 Garcia D, Erkan D. Diagnosis and management ://www.servi​er.ca/sites/​defau​lt/files/​webfo​rm/ validation of the LEFt clinical prediction rule.
of the antiphospholipid syndrome. N Engl J Med produ​c ts/PM_Lixia​na_%2026%20JUL​%20201​ Haematologica 2013; 98: 545–548.
2018; 378: 2010–2021. 7%20EN.pdf?ts=15351​61192​(viewed Feb 2019). 6 7 Wainwright H, Beighton P. Warfarin
32 Foucar CE, Stein BL. JAK2 V617F mutation 50 Levy JH, Ageno W, Chan NC, et al. When and embryopathy: fetal manifestations. Virchows
testing in patients presenting with hepatic how to use antidotes for the reversal of direct Arch 2010; 457: 735–739.
and portal vein thrombosis. JAMA 2017; 317: oral anticoagulants: guidance from the SSC of 6 8 Beyer-Westendorf J, Michalski F, Tittl L, et al. 523
2228–2229. the ISTH. J Thromb Haemost 2016; 14: 623–627. Pregnancy outcome in patients exposed to
 Narrative review
direct oral anticoagulants — and the challenge 7 1 Raskob GE, van Es N, Verhamme P, et al. with a first episode of deep vein thrombosis
of event reporting. Thromb Haemost 2016; 116: Edoxaban for the treatment of cancer-­ of the lower limbs: association with recurrence
651–658. associated venous thromboembolism. N Engl J and new thrombosis. Haematologica 2002; 87:
6 9 Lyman GH, Bohlke K, Khorana AA, et al. Med 2018; 378: 615–624. 515–522.
Venous thromboembolism prophylaxis and 72 Young AM, Marshall A, Thirlwall J, et al. Comparison 75 Schulman S. How I treat recurrent venous
treatment in patients with cancer: American of an oral factor Xa inhibitor with low molecular
thromboembolism in patients receiving
Society of Clinical Oncology clinical practice weight heparin in patients with cancer with venous
anticoagulant therapy. Blood 2017; 129:
guideline update 2014. J Clin Oncol 2015; 33: thromboembolism: results of a randomized trial
3285–3293.
654–656. (SELECT-­D). J Clin Oncol 2018; 36: 2017–2023.
70 Noble SI, Shelley MD, Coles B, et al. Management 7 3 Palareti G. How I treat isolated distal deep vein 76 Pengo V, Denas G, Zoppellaro G, et al.
of venous thromboembolism in patients with thrombosis (IDDVT). Blood 2014; 123: 1802–1809. Rivaroxaban vs warfarin in high-­risk patients
advanced cancer: a systematic review and meta-­ with antiphospholipid syndrome. Blood 2018;
74 Piovella F, Crippa L, Barone M, et al. Normalization
analysis. Lancet Oncol 2008; 9: 577–584. 132: 1365–1371. ■
rates of compression ultrasonography in patients
MJA 210 (11) ▪ 17 June 2019

524